Alnylam continues shift to common diseases, with Roche as hypertension partner

Alnylam sees its next major growth phase tied to moving from rare to prevalent indications, and although it has opted not go it alone in hypertension, the biotech’s deal with Roche allows it to retain upside by keeping U.S. co-commercialization rights, while offering the pharma a chance to build its presence in CV drugs...